In an experimental glioma model, anti-CTLA-4 mAb procured an 80% long-term survival rate, concurrent with enhanced proliferation of CD4+ CD25− T cells and resistance to suppression by Treg cells (351). The gene discussed is CTLA4; the disease is glioma.